SRR15069617
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.650
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V1+0.460
- MYC_TARGETS_V2+0.460
- DNA_REPAIR+0.330
- MITOTIC_SPINDLE+0.320
- MTORC1_SIGNALING+0.210
- GLYCOLYSIS+0.160
- PANCREAS_BETA_CELLS+0.150
- SPERMATOGENESIS+0.110
Top 10 suppressed
- NOTCH_SIGNALING-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- INFLAMMATORY_RESPONSE-0.320
- IL6_JAK_STAT3_SIGNALING-0.300
- INTERFERON_GAMMA_RESPONSE-0.260
- ALLOGRAFT_REJECTION-0.250
- CHOLESTEROL_HOMEOSTASIS-0.240
- MYOGENESIS-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- BILE_ACID_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D6-6823-01A-11R-1915-07 | — | — | 0.878 |
| 2 | 2B4FA61A-C1A7-49BD-9438-2865D386EAF2 | — | — | 0.873 |
| 3 | BS_VT6C6N6K | medulloblastoma | — | 0.871 |
| 4 | BS_8QB4S4VA | Embryonal tumors | — | 0.862 |
| 5 | BS_V72H4RQS | medulloblastoma | — | 0.853 |
| 6 | TCGA-77-7138-01A-41R-2045-07 | — | cohortSQ1 | 0.848 |
| 7 | MNG1194 | — | — | 0.846 |
| 8 | SRR934937 | — | — | 0.846 |
| 9 | BS_RD4D5F9F | medulloblastoma | — | 0.846 |
| 10 | BS_A0DYVX9J | high-grade glioma | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |